Clinical Trial Update: Upadacitinib for Refractory Takayasu Arteritis

View source ↗

Summary

The clinical trial evaluating upadacitinib for refractory Takayasu Arteritis has completed; the update notes the study status as COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Takayasu Arteritis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: Liu Tian | Conditions: Takayasu Arteritis | Status: COMPLETED